Research Article
Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer: A Meta-Analysis
Table 1
Study characteristics of the eight cohort studies.
| | Study (year) | Region | Pathological type | Recruitment period | Total No. of cases | Gender (male/female) | Age (years) | End-point | Cut-off value | Selection method | Therapy | Stage | Follow-up (months) | Multivariate analysis |
| | Jafri et al. (2013) [5] | USA | NSCLC | 2000-2011 | 173 | 116/57 | Median 57 (34-88) | OS, PFS | 18 | ROC curve | No surgery | Metastatic | <60 | Yes | | He et al. (2015) [8] | China | SCLC | 2006-2011 | 365 | 310/55 | Median 60 (22-82) | OS | 19.5 | Cutoff finder | No surgery | Mixed | ≥60 | Yes | | Kim et al. (2016) [9] | Korea | SCLC | 2010-2015 | 186 | 156/30 | Mean | OS | 31.1 | Using chi-squared test | No surgery | Mixed | <60 | Yes | | Bacha et al. (2017) [10] | France | NSCLC | 2010-2012 | 41 | 41/0 | Mean 56.3 | OS | 23.2 | Median value | No surgery | Metastatic | <60 | Yes | | Kobayashi et al. (2018) [11] | Japan | NSCLC | 2009-2014 | 166 | 74/92 | NA | OS, RFS | 22.2 | ROC curve | With surgery | No metastatic | ≥60 | OS—yes; RFS—no | | Ozyurek et al. (2018) [12] | Turkey | NSCLC | 2006-2013 | 112 | 94/18 | Mean | OS | 18 | Median value | No surgery | Metastatic | ≥60 | Yes | | Tomita et al. (2018) [13] | Japan | NSCLC | 2008-2012 | 343 | 175/168 | NA | OS | 37.66 | Cutoff finder | With surgery | No metastatic | ≥60 | Yes | | Shiroyama et al. (2018) [14] | Japan | NSCLC | 2015-2016 | 201 | 135/66 | Median 68 (27-87) | PFS | 18 | Median value | No surgery | Metastatic | <60 | Yes |
|
|
All studies included were retrospective study. NSCLC: non-small-cell lung cancer; SCLC: small-cell lung cancer; OS: overall survival; RFS: recurrence-free survival; PFS: progression-free survival; ROC: receiver operating characteristic curve; NA: not available.
|
